Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

被引：97

作者：

Bardotti, Angela ^{[1
]}

Averani, Giovanni ^{[1
]}

Berti, Francesco ^{[1
]}

Berti, Stefania ^{[1
]}

Carinci, Valeria ^{[1
]}

D'Ascenzi, Sandro ^{[1
]}

Fabbri, Barbara ^{[1
]}

Glannini, Sara ^{[1
]}

Giannozzi, Aldo ^{[1
]}

Magagnoli, Claudia ^{[1
]}

Proietti, Daniela ^{[1
]}

Norelli, Francesco ^{[1
]}

Rappuoli, Rino ^{[1
]}

Ricci, Stefano ^{[1
]}

Costantino, Paolo ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost Srl, I-53100 Siena, Italy

来源：

VACCINE | 2008年 / 26卷 / 18期

关键词：

glycoconjugate vaccines; physicochemical characterisation; Neisseria meningitidis;

D O I：

10.1016/j.vaccine.2008.01.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bacterial capsular polysaccharides covalently linked to an appropriate carrier protein represent the best tool. to induce a protective immune response against a wide range of bacterial diseases, such as meningococcal infections. We describe here the physico-chemical characterisation of glycoconjugate molecules designed to prepare a vaccine against Neisseria meningitidis serogroups A, C, W135 and Y. The use of a selective conjugation chemistry resulted in well. characterised, reproducible and traceable glycoconjugate that can be consistently manufactured at large scale. A pool of physical and spectroscopic methods was used to establish glycosylation ratio, identity, molecular weight profiles, integrity of carrier protein and sites of glycosylation, assuring effective and consistent lots of vaccines. (C) 2008 Published by Elsevier Ltd.

引用

页码：2284 / 2296

页数：13

共 50 条

[11] PROPOSAL FOR A PREVENTION POLICY OF MENINGOCOCCAL DISEASES
DEWALS, P
DEMAEYERCLEEMPOEL, S
BORLEE, I
LECHAT, MF
[J]. MEDECINE ET MALADIES INFECTIEUSES, 1977, 7 (12): : 518 - 524
[12] Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines
Oviedo-Orta, Ernesto
Ahmed, Sohail
Rappuoli, Rino
Black, Steven
[J]. VACCINE, 2015, 33 (31) : 3628 - 3635
[13] Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients
Rennels, MB
Meissner, HC
Baker, CJ
Baltimore, RS
Bocchini, JA
Bradley, JS
Dennehy, PH
Frenck, RW
Hall, CB
Long, SS
McMillan, JA
Powell, KR
Rubin, LG
Clover, RD
Cochi, S
Embree, J
Fischer, MA
Schwartz, B
Makhene, M
Pratt, D
Starke, JR
Swanson, J
Pickering, LK
Ledbetter, EO
Siwek, A
[J]. PEDIATRICS, 2005, 116 (02) : 496 - 505
[14] Erratum zu: MeningokokkenimpfungenErratum to: Vaccines against meningococcal diseases
M. Knuf
U. Vogel
[J]. Monatsschrift Kinderheilkunde, 2014, 162 (3) : 227 - 227
[15] Vaccines for Prevention of Group B Meningococcal Disease Not Your Father's Vaccines
Harrison, Lee H.
[J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2015, 49 (06) : S345 - S354
[16] Vaccines for prevention of group B meningococcal disease: Not your father's vaccines
Harrison, Lee H.
[J]. VACCINE, 2015, 33 : D32 - D38
[17] Glycoconjugate vaccines: an update
Vella, Mairi
Pace, David
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (04) : 529 - 546
[18] Synthetic glycoconjugate vaccines
Bundle, DR
Yu, H
Rich, J
Nitz, M
Wu, X
Ling, CC
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U256 - U256
[19] Improving glycoconjugate vaccines
Susan Jones
[J]. Nature Biotechnology, 2012, 30 (2) : 158 - 158
[20] Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines
Beresford, Nicola J.
Martino, Angela
Feavers, Ian M.
Corbel, Michael J.
Bai, Xilian
Borrow, Ray
Bolgiano, Barbara
[J]. VACCINE, 2017, 35 (28) : 3598 - 3606

← 1 2 3 4 5 →